Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Flynn

Showing results (431-440 of 499) with videos related to

Pageof 50
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 16, 2010
Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinaseJohn K Walker, Shaun R Selness, Rajesh V Devraj, et al.
Neurology. Genetics|August 6, 2020
Disease-modifying effects of an <i>SCAF4</i> structural variant in a predominantly <i>SOD1</i> ALS cohortJulia Pytte, Loren L Flynn, Ryan S Anderton, et al.
Molecular Cancer Therapeutics|August 26, 2021
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by MacrophagesBryan D Smith, Michael D Kaufman, Scott C Wise, et al.
Drug Design and Discovery|May 1, 1997
The herpesvirus protease: mechanistic studies and discovery of inhibitors of the human cytomegalovirus proteaseD L Flynn, D P Becker, V M Dilworth, et al.
Journal of Medicinal Chemistry|July 22, 2011
Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting propertiesBernard L Flynn, Gurmit S Gill, Damian W Grobelny, et al.
Science Translational Medicine|December 5, 2014
PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosisM Teresa Coleman, Ray Y Chen, Myungsun Lee, et al.
Mucosal Immunology|November 4, 2025
Protection against reinfection with Mycobacterium tuberculosis extends across heterologous Mtb lineagesAndrew W Simonson, Michael C Chao, Luke E Hood, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2022
Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitorsTimothy M Caldwell, Michael D Kaufman, Scott C Wise, et al.
Plos One|July 27, 2011
Large scale comparison of innate responses to viral and bacterial pathogens in mouse and macaqueGuy Zinman, Rachel Brower-Sinning, Chineye H Emeche, et al.
Haematologica|December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaJorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Pageof 50

Showing results (431-440 of 499) with videos related to

Sort By:
Pageof 50
Bioorganic & Medicinal Chemistry Letters|March 16, 2010
Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinaseJohn K Walker, Shaun R Selness, Rajesh V Devraj, et al.
Neurology. Genetics|August 6, 2020
Disease-modifying effects of an <i>SCAF4</i> structural variant in a predominantly <i>SOD1</i> ALS cohortJulia Pytte, Loren L Flynn, Ryan S Anderton, et al.
Molecular Cancer Therapeutics|August 26, 2021
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by MacrophagesBryan D Smith, Michael D Kaufman, Scott C Wise, et al.
Drug Design and Discovery|May 1, 1997
The herpesvirus protease: mechanistic studies and discovery of inhibitors of the human cytomegalovirus proteaseD L Flynn, D P Becker, V M Dilworth, et al.
Journal of Medicinal Chemistry|July 22, 2011
Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting propertiesBernard L Flynn, Gurmit S Gill, Damian W Grobelny, et al.
Science Translational Medicine|December 5, 2014
PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosisM Teresa Coleman, Ray Y Chen, Myungsun Lee, et al.
Mucosal Immunology|November 4, 2025
Protection against reinfection with Mycobacterium tuberculosis extends across heterologous Mtb lineagesAndrew W Simonson, Michael C Chao, Luke E Hood, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2022
Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitorsTimothy M Caldwell, Michael D Kaufman, Scott C Wise, et al.
Plos One|July 27, 2011
Large scale comparison of innate responses to viral and bacterial pathogens in mouse and macaqueGuy Zinman, Rachel Brower-Sinning, Chineye H Emeche, et al.
Haematologica|December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaJorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Pageof 50